Top Posts
Trump predicts little progress in potential shutdown talks...
DNC rips JD Vance for fishing with British...
Social Security is 90 years old. We are...
Trump admin unveils groundbreaking tool ‘supercharging’ gov’t efficiency...
Armenia and Azerbaijan leaders seek to ease Russian...
Response to ASX Price and Volume Query
CHARBONE Hydrogen Provides Update on Flagship Sorel-Tracy Project,...
Charbone Hydrogene annonce des mise-a-jour sur le projet...
Homerun Resources Inc. Completes the Assignment of the...
The Nuclear Nexus: Powering the Clean Energy Transition...
  • Home
  • Investing
  • Politics
  • Economy
  • World News
Money Assets Saver
Investing

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

by admin June 4, 2025
June 4, 2025

Phase 1 1 First-In-Human study designed to assess safety   ,   tolerability   , right dose for Phase 2 and early signs of efficacy   of 177Lu-RAD20   2   in individuals with   advanced HER2-positive solid   tumors

Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and biodistribution of 99mTc-RAD202 in humans

Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of RAD202, a proprietary nanobody that targets Human Epidermal Growth Factor Receptor 2 (HER2)-positive expression in a wide array of advanced solid tumors.

The open-label Phase 1 ‘HEAT’ clinical trial is a dose escalation trial of 177Lu-RAD202 that is designed to determine the recommended Phase 2 dose and to evaluate the safety and preliminary clinical activity of this novel radiotherapeutic in individuals with HER2-expressing advanced cancers. The study is currently being conducted at clinical centers across Australia.

‘Dosing patients in the HEAT clinical trial marks an important milestone in our transition to a clinical-stage company,’ said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. ‘Despite progressive improvements in the management of metastatic HER2-positive disease, the majority of patients experience disease progression on current standard of care and require further therapeutic options. The dosing of the first patient in the ‘HEAT’ trial represents a significant step toward achieving RAD202’s potential to address an unmet need for HER2-positive metastatic patients who are progressing or unable to tolerate current treatment options. With RAD202, we hope to provide an option that can meaningfully improve clinical outcomes for HER2-positive patients, while preserving their quality of life.’

HER2 is overexpressed in breast cancer as well as several other solid tumors and represents a validated target in oncology. RAD202 is a proprietary single domain antibody that targets HER2. Ten HER2-positive breast cancer patients previously dosed in a Phase 1 diagnostic study of RAD202 demonstrated clinical proof-of concept as well as the safety and biodistribution of RAD202, validating its potential for the treatment of advanced HER2-expressing cancers 2 . Preclinical findings 3 examining the therapeutic effect in HER2-positive xenografts were also recently reported with 177Lu-RAD202. Collectively, these data further justify first in humans dose finding studies.

‘It is a privilege to be the first centre to administer 177Lu-RAD202, targeting HER2-positive tumors in this Phase 1 clinical trial (HEAT).’ said Dr Aviral Singh, Clinical Head of Theranostics and Nuclear Medicine at St John of God Murdoch Hospital. ‘This opens the possibility of novel therapeutic avenues for patients with aggressive tumor types, including breast, ovarian, gastric, pancreatic, bladder, and several other cancers. With the trust put in us by Radiopharm, we look forward to a successful trial with beneficial outcomes for our patients.’

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com .

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

________________________________

1 clinicaltrials.gov/study/NCT06824155
2 Zhao et al, Molecular Pharmaceutics 2021 18 (9), 3616-3622
3 Altunay B. et al, EP-0136, Eur J Nucl Med Mol Imaging (2024) 51 (Suppl 1): S1–S1026. DOI: 10.1007/s00259-024-06838-z

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

previous post
Charbone Hydrogene a execute un financement de 50 millions USD pour accelerer son expansion en hydrogene en Amerique du Nord, facilite par US Capital Global
next post
Massive Russia sanctions package stalls as Trump pushes for Ukraine peace talks

You may also like

Response to ASX Price and Volume Query

August 14, 2025

Charbone Hydrogene annonce des mise-a-jour sur le projet...

August 14, 2025

CHARBONE Hydrogen Provides Update on Flagship Sorel-Tracy Project,...

August 14, 2025

The Nuclear Nexus: Powering the Clean Energy Transition...

August 14, 2025

Homerun Resources Inc. Completes the Assignment of the...

August 14, 2025

Silver47 Unveils Multiple Premier Exploration Targets with Strong...

August 13, 2025

Osisko Metals Intersects 731 Metres Averaging 0.29% Cu...

August 13, 2025

Crypto Market Update: Trump-Backed World Liberty Announces US$1.5B...

August 13, 2025

Sranan Gold Initiates Diamond Core Drilling Program on...

August 13, 2025

Lithium Prices Surge After CATL Halts Major Mine...

August 13, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Trump predicts little progress in potential shutdown talks with ‘crazy’ Schumer, Jeffries

      August 14, 2025
    • DNC rips JD Vance for fishing with British foreign secretary in latest bizarre attack; Republicans hit back

      August 14, 2025
    • Social Security is 90 years old. We are making it smarter, better, faster under Trump

      August 14, 2025
    • Trump admin unveils groundbreaking tool ‘supercharging’ gov’t efficiency to ‘win the race’ for AI dominance

      August 14, 2025
    • Armenia and Azerbaijan leaders seek to ease Russian and Iranian concerns after US-brokered peace deal

      August 14, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 moneyassetssaver.com | All Rights Reserved

    Money Assets Saver
    • Investing
    • Politics
    • Economy
    • World News